Nonglycosidic Agonists of Invariant NKT Cells for Use as Vaccine Adjuvants | Zendy

Reddy B. Gopal | Zendy; Silk Jonathan D. | Zendy; Salio Mariolina | Zendy; Balamurugan Rengarajan | Zendy; Shepherd Dawn | Zendy; Ritter Gerd | Zendy; Cerundolo Vincenzo | Zendy; Schmidt Richard R. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Nonglycosidic Agonists of Invariant NKT Cells for Use as Vaccine Adjuvants

Author(s) -

Reddy B. Gopal,

Silk Jonathan D.,

Salio Mariolina,

Balamurugan Rengarajan,

Shepherd Dawn,

Ritter Gerd,

Cerundolo Vincenzo,

Schmidt Richard R.

Publication year - 2009

Publication title -

chemmedchem

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.817

H-Index - 100

eISSN - 1860-7187

pISSN - 1860-7179

DOI - 10.1002/cmdc.200800354

Subject(s) - cd1d , natural killer t cell , priming (agriculture) , antigen , vaccination , immunology , immunotherapy , immune system , biology , t cell , botany , germination

Based on the crystal structures of human α‐GalCer–CD1d and i NKT–α‐GalCer–CD1d complexes, nonglycosidic analogues of α‐GalCer were synthesized. They activate i NKT cells resulting in dendritic cell maturation and the priming of antigen‐specific T and B cells. Therefore, they are attractive adjuvants in vaccination strategies for cancer and infectious diseases.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research